Siavash Es'haghi’s Post

An exciting discovery in lung cancer research! Memorial Sloan Kettering Cancer Center's team, led by Dr. Natasha Rekhtman, has identified a new rare type of small cell lung cancer (SCLC) that differs significantly from previously known forms. Unlike traditional forms of SCLC, this subtype exhibits unique molecular and genetic characteristics, paving the way for personalised treatment approaches and targeted therapies. This discovery underscores the crucial role of advanced molecular profiling in uncovering hidden complexities within cancers, offering new hope for more precise diagnostics and improved outcomes for patients with this challenging form of lung cancer. Dive deeper into this important advancement here: https://lnkd.in/eYsXfvCR #CancerResearch #LungCancer #Oncology #PrecisionMedicine #MSK

Interesting #preclinical research that looked at tumor, tumor rim and adjacent tissue in liver tumors to examine how this type of T cell acted in the tumor and tumor environment. Always great to see new possibilities in #immunotherapy and #cancertreatment.

According to early clinical data, a new experimental blood test can detect stage 1 and 2 pancreatic cancer with 97% accuracy. Although pancreatic cancer accounts for just 3% of new cancer diagnoses, it's one of the most fatal due to the difficulty of detecting it at an early stage. A quicker and earlier diagnosis means it's much more likely the cancer can be surgically removed before it spreads to other parts of the body, significantly increasing the likelihood of a full recovery. The clinical trial included patients from the US and Asia and will now be studied on a larger scale. #liquidbiopsy #IVD #cancerdiagnostics

Interesting discovery, with the use of AI, upon an important role of liver T-cells for the treatment of liver cancer. Mucosal-associated invariant T (MAIT) cells attach to the tumour, but are supressed by a distinct signalling mechanisms of macrophages, which is only found in some individuals. With the use of immunotherapy this mechanism could be blocked to treat this disease. New innovations happen all the time! #NCI #ArtificialIntelligence #Cancer #Immunotherapy

Early dg - and prevention showed clear costs benefit for all, improved HDI / GPD It has become crucial to understand the potential costs and benefits of each intervention to determine whether they provide good value. Economic evaluations of health-care interventions have become more common in the medical and health economics literature and are increasingly being used to inform reimbursement and coverage decisions in Australia, Canada, the United Kingdom, and other European countries , although results from economic evaluations have not traditionally been used in the United States for these purposes. Reimbursement and coverage decisions influence patient care, it is important for both decision makers and medical practitioners to be able to adequately interpret the design, the results, and the conclusions of economic evaluations which strongly turns in New technologies and early biomarkers and strategies accompanied by necessary investments for Prevention.

🔬 Blood tests can identify lung cancer relapses with precision! 💉 Exciting advancements in science are revolutionizing the way we detect relapses in lung cancer. A study (Nicolai Birkbak) shows that blood tests could play a crucial role in identifying relapses early, offering a less invasive and highly accurate method for monitoring patients. Learn more about this discovery and its implications for cancer care! 👉 Read the full article here: https://lnkd.in/d9mkHzCp #sciencenewsdk #LungCancer #BloodTests #EarlyDetection #CancerResearch #NovoNordiskFoundation

The Centenary Institute has received grant funding worth $199,816.00 over two years from Cancer Australia to lead new research efforts targeting chemotherapy resistance in ovarian cancer patients. Dr Alex Cole from the Centenary Institute’s Centre for Biomedical AI, will lead the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy. Ovarian cancer, one of the deadliest cancers affecting women worldwide, sees high rates of chemotherapy resistance hinder treatment success and patient survival. With this funding, Dr Cole hopes to enhance the effectiveness of chemotherapy and improve ovarian cancer treatment and survival rates. #ovariancancer #medicalresearch #centenaryinstitute #cancer #chemotherapy 

Breast Cancer Blood Test Hailed As A Breakthrough! A new type of “ultra-sensitive” blood test can predict if breast cancer will return in high-risk patients long before they relapse and symptoms show up on scans, according to scientists at the Institute of Cancer Research (ICR) in London, England... https://bit.ly/3T9NteQ #cancer #breastcancer #bloodcancer #cancersucks #health #cancersurvivor #c #cancerawareness #cancerfighter #oncology #oncologia #chemotherapy #cancerwarrior #cancersupport #cancerresearch #chemo #cancertreatment

🅾🅻🅳 🅳🆁🆄🅶🆂, 🅽🅴🆆 🆄🆂🅴🆂 !! In a groundbreaking study, researchers have unveiled a new facet of aspirin's role in #cancer prevention. Published in Cancer and led by Marco Scarpa MD, PhD, of the University of Padova, the study reveals that aspirin may bolster the body's immune surveillance against colon cancer, marking a significant stride in our understanding of cancer immunoprevention. The findings suggest that regular aspirin use could enhance the immune system's ability to detect and combat colorectal cancer cells, potentially reducing the spread of the disease. This discovery could pave the way for new strategies in cancer treatment, emphasizing the importance of immunosurveillance in managing colorectal cancer. #immunooncology #cancer

#ScientificWednesday: Updates on Cancer Therapy: Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 🔬 Exciting advancements in cancer research! A recent study "Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers" by Dr. Monali Praharaj and team reveals the potential of the glutamine antagonist JHU083 in reprogramming tumor-associated macrophages (TAMs) to fight myeloid-rich prostate and bladder cancers. 🧬 🔐 Key Findings: 🔑 Tumor Growth Inhibition JHU083 reprograms TAMs to increase tumor cell phagocytosis and reduce proangiogenic capacities. 🔑 Enhanced Immune Response Promotes proinflammatory signaling and immune-proliferative pathways. 🔑 Metabolic Disruption Causes global shutdown of glutamine-utilizing pathways, leading to tumor cell apoptosis. 🔑 Therapeutic Potential Offers a promising approach for treating immunosuppressive TAM-rich tumors. This research underscores the importance of targeting TAM metabolism to boost antitumor immunity and improve cancer immunotherapy outcomes. A promising step forward in the fight against cancer! 💪🔬 🔖 Read more here: https://lnkd.in/gZ7pczyP #CancerResearch #Immunotherapy #MedicalBreakthrough #Oncology #HealthcareInnovation